 EMERYVILLE, Calif., May 13, 2021 GLOBE NEWSWIRE -- 4D Molecular Therapeutics Nasdaq: FDMT, a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced financial results for the first quarter of 2021, and provided operational highlights. 